Comparative Pharmacology
Head-to-head clinical analysis: MAXIDEX versus STERANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXIDEX versus STERANE.
MAXIDEX vs STERANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MAXIDEX (dexamethasone) is a potent glucocorticoid that binds to the glucocorticoid receptor (GR), leading to modulation of gene expression and inhibition of inflammatory mediators such as prostaglandins and leukotrienes. It suppresses immune response through inhibition of cytokine production (e.g., IL-1, IL-2, TNF-alpha) and reduces vasodilation and vascular permeability.
Sterane (prednisolone) is a glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production.
One to two drops of the 0.1% ophthalmic suspension into the conjunctival sac every hour during the day and every two hours at night initially; after improvement, reduce to one drop every four hours, then one drop three to four times daily.
100 mg orally every 12 hours
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours for dexamethasone; in ocular tissues, half-life may be prolonged due to local retention, but systemic half-life is short with minimal accumulation.
Terminal elimination half-life is approximately 2.5 hours (range 2-3 hours) in adults with normal renal function; clinically, this supports twice-daily dosing
Primarily hepatic metabolism via CYP3A4; renal excretion of metabolites accounts for <15% unchanged drug; biliary/fecal elimination of metabolites predominates.
Renal (approximately 70% as unchanged drug and glucuronide conjugate), biliary/fecal (approximately 30%)
Category C
Category C
Corticosteroid
Corticosteroid